Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure Patients

NCT07695090 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure With Reduced Ejection Fraction

Interventions

DRUG: Lumacaftor 200 MG
DRUG: Placebo

Sponsor

Qanatpharma AG

Collaborators

[object Object]